{"organizations": [], "uuid": "ec12b51a94dea982eef6618fa391477e58439bd2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-meridian-bioscience-reports-q1-gaa/brief-meridian-bioscience-reports-q1-gaap-eps-of-0-15-idUSASB0C2B8", "country": "US", "domain_rank": 408, "title": "BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T20:25:00.000+02:00", "replies_count": 0, "uuid": "ec12b51a94dea982eef6618fa391477e58439bd2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-meridian-bioscience-reports-q1-gaa/brief-meridian-bioscience-reports-q1-gaap-eps-of-0-15-idUSASB0C2B8", "ord_in_thread": 0, "title": "BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15", "locations": [], "entities": {"persons": [], "locations": [{"name": "cytomegalovirus", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "meridian bioscience inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "thomson", "sentiment": "none"}, {"name": "magellan", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Meridian Bioscience Inc:\n* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE\n* Q1 NON-GAAP EARNINGS PER SHARE $0.15 * Q1 GAAP EARNINGS PER SHARE $0.15 * Q1 REVENUE $52.3 MILLION VERSUS I/B/E/S VIEW $49 MILLION * Q1 EARNINGS PER SHARE VIEW $0.15 -- THOMSON REUTERS I/B/E/S\n* REAFFIRMS FY 2018 NON-GAAP EARNINGS PER SHARE VIEW $0.65 TO $0.68\n* REAFFIRMS FY 2018 GAAP EARNINGS PER SHARE VIEW $0.59 TO $0.62\n* SEES FY 2018 REVENUE $207 MILLION TO $212 MILLION * ‍CONTINUING TO WORK WITH FDA REGARDING USE OF VENOUS BLOOD WITH MAGELLAN‘S LEADCARE TESTING SYSTEMS​\n* ‍MAGELLAN LEAD TESTING BUSINESS UNIT REVENUES DECLINED BY 20% IN QUARTER YEAR-OVER-YEAR​\n* ‍ANTICIPATE A REBOUND IN MAGELLAN BUSINESS IN Q2 AND A RETURN TO GROWTH FOR QUARTER​\n* ‍ILLUMIGENE CMV, FIRST MOLECULAR TEST FOR CYTOMEGALOVIRUS, IS TARGETED TO LAUNCH LATE IN CALENDAR YEAR 2018​\n* ‍BUSINESS OUTLOOK FOR FISCAL 2018 REMAINS UNCHANGED​ * FY2018 EARNINGS PER SHARE VIEW $0.66, REVENUE VIEW $207.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T20:25:00.000+02:00", "crawled": "2018-01-26T21:25:52.010+02:00", "highlightTitle": ""}